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Abstract
During the last few decades we have become accustomed to the idea that viruses can cause tumors. 
It is much less considered and discussed, however, that most people infected with oncoviruses will 
never develop cancer. Therefore, the genetic and environmental factors that tip the scales from 
clearance of viral infection to development of cancer are currently an area of active investigation. 
Microbiota has recently emerged as a potentially critical factor that would affect this balance by 
increasing or decreasing the ability of viral infection to promote carcinogenesis. In this review, we 
provide a model of microbiome contribution to the development of oncogenic viral infections and 
viral associated cancers, give examples of this process in human tumors, and describe the 
challenges that prevent progress in the field as well as their potential solutions.
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1. Introduction
As the human lifespan lengthens, the incidence of cancer worldwide is also increasing. The 
World Health Organization predicts the frequency of cancer occurrence to increase by 70% 
over the next two decades [1,2], indicating a rise in the global cancer epidemic. One of the 
established causes of cancer is viral infection, which is responsible for 20% of the global 
cancer burden [3]. Among these infections, the most common are Human Papilloma Virus 
(HPV) and Hepatitis C/B viruses with other less frequent contributors being Epstein - Barr 
virus (EBV), Human Immunodeficiency Virus (HIV), and Kaposi Sarcoma Herpesviruses 
(KSHV) [4]. These viruses use two different strategies to cause cancer: first, by directly 
affecting host cell machinery (e.g. HPV); and second, indirectly, by inhibiting the human 
immune system (e.g. HIV) [5,6]. It is common knowledge that the development of some 
cancers require viral infection, such as HPV for cervical cancer. It is less known, however, 
why most people infected with oncogenic viruses will never develop cancer.
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A hint in solving this puzzle may come from studies demonstrating the crucial role of 
microbiota (collection of microorganisms living with the host) in the course of viral 
infections [7–10]. Moreover, microbiota have been recently implicated in different diseases 
associated with aberrant immune responses ranging from diabetes and autoimmunity to 
obesity and cancer [11,12]. For example, a recent epidemiologic study reported an 
association between antibiotic exposure and the development of several malignancies such 
as esophageal, gastric, pancreatic, lung, prostate, and breast cancers [13].
Studies thus far have placed emphasis on gastrointestinal microbiota and its role in the 
development and progression of gut-associated malignancies [14]. For example, 
Helicobacter pylori causes gastric adenocarcinoma and is a classic case of oncogenic 
bacteria [15]. Intestinal infections with other bacteria such as Salmonella typhi [16] and 
Streptococcus gallolyticus (bovis) [17] were also linked to the development of hepatobiliary 
and colorectal cancers, respectively. These studies represent additional support for the 
hypothesis that some microbiota members as an understudied environmental factor 
contributing to protection from or the development of virus-associated cancers. Even though 
the gut microbiome represents the majority of bacteria in the human microbiome [18], other 
body sites such as the vagina and oral cavity have been explored for their participation in 
cancer development and progression.
Although oncogenic properties of virus and bacteria, individually, are popular topics, the 
interaction between these in the context of cancer has not been well investigated. In recent 
years, we have witnessed an increasing number of attempts to interrogate this three-way 
interaction, particularly the influence of microbiota on the progression and acquisition of 
oncogenic viral infections. However, the question whether bacteria are beneficial or harmful 
in this context remains unanswered for many cancers. In this review, we provide a model of 
microbiome contribution to the development of oncogenic viral infections, discuss examples 
of this process in human tumors, and describe obstacles in the field and their potential 
solutions.
2. Model description
The role of bacteria (and bacterial microbiota) in viral infections leading to cancer can be 
assigned to two broad categories: bacteria that influence viral particles, and bacteria that 
affect host interaction with viral infection.
On the one hand, healthy microbiota was shown to contribute to infections by interacting 
with viruses directly and through bacterial byproducts [7–10]. It was reported that 
commensal microbiota augment the transmission of mouse mammary tumor virus [19,20], 
bacterial lipopolysaccharides enhance virion stability of poliovirus [21], and enteric bacteria 
promote norovirus infection through histo-blood group antigen-like substances [9,22]. On 
the other hand, healthy microbiota are critical for immune system development, especially 
on mucosal surfaces [23]. Antibiotic-treated mice exposed to mucosal influenza virus were 
observed to have impaired innate and adaptive antiviral immune responses and delayed 
clearance of the virus [24]. These and other studies define microbiota as a putatively 
important factor for the development of virus-associated cancers.
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Herein we propose a model for the three-way interaction between bacteria, virus, and 
mammalian host, highlighting two distinct mechanisms for the contribution of microbiota to 
virus-associated cancers. The first involves the direct effect of interaction of bacteria and 
bacterial products on viruses, primarily affecting their infectivity (Fig. 1A). The second 
involves bacteria-host interactions leading to changes in host gene expression and 
subsequent activation/repression of viral expression or direct promotion of inflammation 
synergizing with the tumorigenic effects of a virus (Fig. 1B). There is evidence to suggest 
that the role of bacteria can be positive or negative in terms of disease progression with each 
of these cases. In this review, we discuss conventional tumor viruses and explore the role of 
gut, vaginal, and oral microbiota components in both of these mechanisms.
3. Gastrointestinal microbiome
The gut microbiome is the largest microbial community in the human body. Recent 
discoveries show its involvement in a variety of functions, including immune system training 
and metabolism regulation [25–27]. Separate members of gut microbiota as well as 
dysbiosis (i.e. non-specific alterations of mammalian microbial communities) have been 
implicated in disease development and progression. Among most prominent examples are 
diabetes [28], irritable bowel disease [25], and cancer [29,30]. Additionally, intestinal 
microbiota has been implicated in modulating the effect of different anti-cancer treatments 
[31–33]. Helicobacter species, in particular Helicobacter pylori, is the most well studied 
bacterial member of the gut community that causes cancer [15].
3.1. Hepatitis viruses
The second leading cause of cancer mortality is liver cancer [34]. The most prevalent 
histologic type of primary liver cancer is hepatocellular carcinoma (HCC) [35] primarily 
caused by chronic infection with hepatitis B (HBV) or hepatitis C (HCV) virus [36]. 
Although both viruses can cause cancer, HCV currently attracts stronger interest from the 
scientific community possibly due to the absence of a vaccine against HCV.
The pathogenicity of both HBV and HCV involves a combination of direct and indirect 
mechanisms. The HCV encoded core, nonstructural protein 5A (NS5A) and NS3, and HBV 
encoded X antigen (HBx) are able to promote host cell proliferation. Both viruses are 
similarly capable of blocking cell immune response, inhibiting apoptosis while promoting 
angiogenesis and metastasis. By contrast, chronic inflammation caused by oxidative stress 
also contributes to the process of carcinogenesis [6].
While HCV is oncogenic, not all patients suffering from chronic hepatitis C will develop 
cancer. One of the first indications that bacteria may be a critical parameter in liver cancer 
came with the observation that mice infected with Helicobacter were developing strong 
inflammatory responses leading to hepatocellular carcinoma [37]. Another group later found 
an association between H. pylori specific antibody levels and HCV associated hepatocellular 
carcinoma [38]. Helicobacter DNA was also found in liver and was associated with hepatitis 
C induced cirrhosis [39], which indicates the ability of H. pylori to invade the liver and 
putatively contribute to disease development (Fig. 2B). However, a more recent study 
conducted on HCV transgenic mice colonized with H. pylori found no indication of bacteria 
Vyshenska et al. Page 3
Semin Immunol. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
translocation into the liver and no promotion of tumorigenesis [40]. Whether this 
experimental system failed to promote carcinogenesis, or H. pylori does not contribute to 
HCV-associated liver cancer, remains unknown.
Another Helicobacter species, Helicobacter hepaticus, has been shown to cause chronic 
hepatitis and liver cancer in rodents [37]. In the following study, Fox et al. have shown that 
presence of H. hepaticus in the gut lumen promotes development of hepatocellular 
carcinoma in HCV infected mice, acting synergistically with viral infection [41]. This 
process did not require bacterial invasion. Fox et al. also showed that in an aflatoxin B1 
HCC mouse model, H. hepaticus induced the nuclear factor-κB (NF-κB) along with 
downstream innate and Th1-type adaptive immunity. In a HCV transgenic mouse model, 
they also observed increased gene expression of an NF-kB-dependent inflammatory 
chemokine (CXCL9) in mice colonized with H. hepaticus [6,41,42] (Fig. 2C, D). 
Concordantly in both models, tumor growth was accelerated in the presence of H. hepaticus. 
These bacteria, detected in human intestine [43] and liver [44–46], is suspected to contribute 
not only to cirrhosis [47] and HCC [44], but also to a set of other conditions such as 
inflammatory bowel disease [43] and prostate cancer [48]. Consequently, this data suggests a 
synergistic relationship between H. hepaticus and HCV in human cancers.
The link between HBV related oncogenesis and gut microbiota has also been reported. In 
2011, Chen et al. found that enteric fungi diversity was positively correlated with a worsened 
disease state in chronic HBV infection [49]. More recently, Chou et al. showed that in adult 
C3H/HeN mice transfected with HBV, elimination of gut microbiota with antibiotics 
resulted in viral persistence phenotypes, including prolonged HBV surface antigens 
(HBsAg) presence, impaired anti-HBs production, and limited HBV core antigen (HBcAg)-
specific IFN-γ–secreting splenocytes [50]. Although these results suggest that the 
persistence of HBV infection in antibiotic-treated mice is attributed to an ineffective 
adaptive humoral and cellular immune response, specific bacteria were not identified in this 
study. Other studies observed that a decrease in fecal Bifidobacterium populations was 
associated with liver disease progression of HBV infection in humans [51,52]. In addition, 
Bifidobacterium species have been shown to decrease the protein and transcript levels of 
HBsAg in a HBV-transfected human hepatoma cell line [53]. Interestingly, Bifidobacterium 
can also increase host gene expression of IFN-signaling components such as STAT1 [53] and 
lower serum cholesterol levels [54–56]. Furthermore, IFN stimulation have been shown to 
downregulate lipid metabolic pathways [27], known in host cells to be necessary for HBV 
production [57,58]. Therefore, we propose that Bifidobacterium species are able to stimulate 
IFN-dependent pathways which results in a downregulation of lipid metabolism and a 
reduction in HBV infection (Fig. 2A). Further experimentation is warranted to establish how 
the antiviral and antitumor effects of these bacteria contribute to overall protection against 
malignancy.
4. Cervicovaginal microbiome
Despite the fact that microbiota in the vagina is less diverse than in the gut it can also 
contribute to protection against or susceptibility to some illnesses, especially sexually 
transmitted diseases. Healthy stable vaginal microbiome is thought to be a first line of 
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defense [59,60] against diseases caused by opportunistic and true pathogens: outcompeting 
dangerous bacteria or protecting the host with bacterial by-products, in particular lactic acid 
[61–64] and hydrogen peroxide [60,65,66].
Lactobacilli, commonly considered as such beneficial microbes, represent the dominant 
genus [67,68] in healthy vaginal microbiota. However, this does not seem to be universally 
applicable as Gardnerella-dominated microbiomes were observed as another frequent type in 
some populations [69]. Disruption of healthy vaginal microbiota (bacterial vaginosis - BV) 
[67] may increase risks of sexually transmitted infections (STI) [70], and even contribute to 
the disease progression, putatively, including cancer development.
4.1. Human papillomavirus
Human papillomavirus (HPV) is the most common STI in the United States and although 
the majority of HPV types are non-carcinogenic, there are at least 13 high-risk oncogenic 
types (hrHPV), with HPV16 and HPV18 leading the list [71,72]. One of the most common 
cancers caused by HPV infection remains cervical squamous cell carcinoma. However, HPV 
is also linked to anal, vulvar, vaginal, penile and head-and-neck carcinomas [73].
hrHPV infections remain the main predictors for cervical intraepithelial neoplasia (CIN), 
precursor to tumor, and cervical cancer development itself [74–76]. HPV infects basal 
epithelial cells. After infection HPV either exist in episomal form or can integrate into the 
cell genome causing genomic instability. Expression of HPV oncogenes E6 and E7 is also 
dependent on integration: in episomal form expression of E2 protein keeps expression levels 
of E6/7 low, but during integration open reading frame of E2 gene is disrupted and E2 no 
longer is able to control HPV oncogenes. E6, E7 and E5 HPV oncoproteins retain 
keratinocytes in proliferative state, avoiding apoptosis and clearance by the immune system. 
It was also reported that HPV is able to promote angiogenesis and deregulate cellular 
energetics [77].
Although hrHPV type infections are necessary for development of cervical cancer, in most 
cases the virus is cleared by the host. Only 0.3–1.2% of women eventually develop cervical 
cancer [78] which means that additional risk factors contribute to the disease progression 
and vaginal microbiota is possibly one of them. It appears that both, the protective role of 
normal vaginal microbiome and the contribution of certain pathogens, may play a role in 
development of cervical intraepithelial lesions and cancer.
While Lactobacillus gasseri-dominated vaginal bacterial communities are associated with 
faster clearance of HPV infection [79], dysbiosis, and bacterial vaginosis are associated with 
CIN development and progression [80,81] (Fig. 3D). Furthermore, it is unclear whether 
bacteria in the disrupted vaginal microbiome affect host susceptibility, virus survival, or 
infectivity. Some evidence (discussed below), however, points to the possible involvement of 
Prevotella genus that contains Prevotella bivia, a microbe known to be associated with 
bacterial vaginosis.
Normally inhibited by Lactobacillus [65], Prevotella species may become abundant when 
the homeostasis of the vaginal microbial community is disrupted by such factors as diet or 
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hormone status [82] (Fig. 3E). Recent findings also suggest host genetics as an important 
factor in Prevotella outgrowth [82]. Increasing in abundance, Prevotella species may provide 
nutrients (e.g. ammonia and amino acids), to other members of microbial community such 
as Gardnerella vaginalis and Peptostreptococcus anaerobius [83,84], and thus diversify the 
vaginal microbial landscape [69] (Fig. 3F). Furthermore, multiple studies of Prevotella 
associations with bacterial vaginosis and cervicitis [68,82,85] point to Prevotella as a 
conductor orchestrating the state of vaginal microbiomes. Additionally, a clear link between 
Prevotella genus and HPV infection [86], in particular with high risk HPV types [87], has 
been established. Adding to the potential importance of these microbes, Prevotella was 
cultured from cervical cancer samples in 1993 [88], and more recently we detected it as the 
most abundant genus in cervical cancer biopsies (unpublished). Finally, increased expression 
of NF-κB, Toll-like receptor (TLR), NOD-like receptor, and TNF-α signaling pathways in 
antigen presenting cells from blood, and increased levels of pro-inflammatory cytokines 
from vaginal lavage have been associated with microbial communities that include 
Prevotella [69]. Thus, it is likely that Prevotella or Prevotella-driven vaginal microbiome 
may act in favor of persistent HPV infection promoting cervical cancer development through 
upregulation of cell proliferation and chronic inflammation.
Aside from the common members of vaginal microbiota, pathogens have also been 
suspected in the promotion of HPV infection. For example, Chlamydia trachomatis, has 
been studied for some time as a potential co-factor of HPV in the process of tumorigenesis 
[89,90]. Investigation of the potential mechanism of how C. trachomatis infection may 
influence HPV infection and cancer development are underway. For example, it was 
demonstrated that C. trachomatis can decrease the expression of caveolin-1 (tumor 
suppressor) and increase C-myc mRNA levels (oncogene) [91]. A study conducted by Paba 
et al. found a correlation between C. trichomonas infection and upregulation of cytoplasmic 
and nuclear NF-kB, VEGF-c and survivin in HPV-positive CINs and cervical cancer [92], 
which points out to the possibility that C. trachomatis can also act through the NF-kB 
pathway, promoting local inflammation, cell survival and proliferation (Fig. 3G). Despite 
many studies and even mechanistic research, the scientific community has not yet reached a 
consensus about whether C. trachomatis plays a causal role in aiding HPV in carcinogenesis. 
Thus epidemiological studies that would investigate the temporal relationship between C. 
trachomatis and HPV infections are required to settle this long standing debate.
4.2. Human immunodeficiency virus
Human Immunodeficiency Virus (HIV) is a carcinogenic virus in its ability to act as a co-
factor for EBV and KSHV in carcinogenesis [93]. Immunosuppression, chronic antigenic 
stimulation, and cytokine dysregulation are reported to contribute to HIV-associated cancer 
development. However, the main cause of HIV-related cancer development remains 
immunosuppression: the inability of the immune system to recognize and clear host cells 
infected with potentially oncogenic viruses enables those viruses to express oncogenic 
proteins, which in its turn leads to cancer development [6]. Due to the absence of vaccines 
and ways to eliminate HIV, understanding risk factors contributing to the pathogenesis of 
HIV infections becomes a priority.
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Sexual transmission is one of the most common ways to acquire HIV, suggesting that 
vaginal microbiota may influence this process. Indeed, several studies found an association 
between the risk of HIV infection and bacterial vaginosis [94–96]. However, it is still 
unclear whether the absence or overgrowth of some bacteria in the vaginal microbiota would 
make women more susceptible to or protected from HIV infection.
In 2013, Aldunate et al. showed that physiological concentrations of lactic acid can 
inactivate different HIV subtypes [97]. Thus, Lactobacillus spp. which is known to produce 
lactic acid, may play an important role in protection against sexually transmitted diseases, 
including HIV [98] (Fig. 3A). In contrast, bacterial vaginosis predisposes females to 
sexually transmitted diseases [99], and can reactivate latent HIV infection [100,101]. 
Evidence suggests that bacteria are not acting directly on HIV, but rather via bacterial by-
products (e.g. butyric acid) [105,106]. Specifically, immunosuppression caused by HIV is an 
important step in the establishment of lifelong latent infection and avoidance of host 
immune response. Latently infected cells harbor the HIV proviral DNA genome integrated 
into heterochromatin, allowing the persistence of transcriptionally silent proviruses [102]. 
Hypoacetylation of histone proteins by histone deacetylases (HDAC) is involved in the 
maintenance of HIV latency by repressing viral transcription [103,104]. Interestingly, 
butyric acid-producing bacteria (Fusobacterium nucleatum, Porphyromonas gingivalis, 
Clostridium cochlearium, Eubacterium multiforme, and Anaerococcus tetradius), residing in 
different mucosal environments (gut, vaginal, and oral cavities), are capable of reactivating 
latent HIV infection through host HDAC pathways [105,106] (Figs. 3B, 4B). Butyric acid is 
known to inhibit the enzymatic activity of HDAC by directly competing with HDAC 
substrate at the catalytic center of the enzyme [107] (Fig. 4A). Butyrate originating from 
microbiota has been shown to promote immunosuppressive/immunoregulatory effects [108]. 
Considering this, it is plausible that in addition to reactivating viruses, butyric acid can 
inhibit antiviral immunity in the host directly.
Additionally, the epidemiological synergy of sexually transmitted infections (STI) with HIV 
transmission was reported in multiple studies. Ferreira et al. found that stimulation of HIV 
infected T-cells with TLR3, 4, or 5 ligands leads to enhanced HIV-1 replication via direct 
activation of HIV long terminal repeats, or by inducing secreted factors that promote HIV 
replication [109]. Among the pathogens suspected to contribute to HIV infection and 
reactivation, one player stands out - Neisseria gonorrhoeae: it was found to be highly 
associated with HIV infection [110] and activation of HIV expression [109,111,112]. Not 
only does N. gonorrhoeae drives an increase of activated CD4+ T-cells [111] and pro-
inflammatory cytokines in genital epithelial cells such as IL-6, IL-8 and TNFα [109], but 
exposure to the pathogen directly drives HIV expression in T cells in NF-kB and AP-1 
dependent manner [109,111]. Malott et al. showed that N. gonorrhoeae by-product heptose-
monophosphate is necessary for invoking these host responses [111] (Fig. 3C). Thus, the 
course of HIV infection can be altered negatively (by lactate producers) or positively (by 
butyrate producers or N. gonorrhoeae), preventing or favoring, respectively, development of 
immunodeficiency, which may increase susceptibility to EBV and KSHV infection, which 
are responsible for a substantial proportion of HIV-related cancers.
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5. Oral microbiome
Although many studies have been devoted to HIV in the genital tract, the connection 
between HIV, oral microbiome, and periodontal disease has also drawn the attention of the 
scientific community [113–116] [105,106]. Recent works have found associations between 
periodontitis, a chronic inflammatory disease of the periodontium occurring in response to 
bacterial infection, and several types of oral cancers [117–120]. Periodontal disease is 
marked by a disruption in the oral microbiome and is often associated with a shift to 
anaerobic bacteria such as Porphyromonas gingivalis, that has also been directly implicated 
in cancers [121,122]. Although common risk factors for these cancers include smoking and 
alcohol abuse, there are an increasing number of cases where no significant smoking or 
drinking history has been reported. Among other risk factors are viral infections HIV, HPV, 
herpesviruses (EBV, HCMV, KSHV) and oral hygiene [123]. Herpes-viruses, particularly 
EBV and KSHV, are known to cause cancer in the context of immunodeficiency caused by 
HIV/AIDS [124].
5.1. Herpesviruses
Herpesviruses have recently been implicated in the progression of periodontitis in the oral 
cavity [125–129]. Among these viruses, KSHV, EBV, and HCMV have also been associated 
with head and neck cancers, primarily those found in the mouth. A hallmark of 
herpesviruses is their ability to establish life-long latent infection in host cells. During latent 
infection, certain viral genes are repressed and viral progenies are not produced. The 
reactivation of lytic cycle genes in virus-infected cells marks the production of viral progeny 
which ultimately leads to host cell lysis. Both latent and lytic cycle genes are critical for 
tumorigenesis and the evasion of host immune response. In addition, studies exploring co-
infection and crosstalk between these viruses as well as with HIV has shown direct (virus-
virus) and indirect (through host immunity) interactions, most notably affecting the 
transition between latent and lytic viral cycles [124,130].
Human cytomegalovirus (HCMV) is not usually regarded as an oncogenic virus. However, 
HCMV infections have been implicated in malignant diseases from different cancer entities 
and can cause fatal diseases in immunocompromised patients [131]. Some evidence also 
suggests its role in sustaining chronic inflammation in the progression of cancer [132]. 
However, in the case of oral squamous cell carcinomas, Saravani et al. reported that only 
6.3% of 48 patient samples were found to have detectable HCMV [133]. Although this 
patient population had low incidence of HCMV detection, it does not discount the possibility 
of synergy between HCMV and periodontal disease (not explored) in the development of 
oral cancer subtypes. In fact, HCMV has been associated with active periodontal disease and 
P. gingivalis [126–129]. Thus, strengthening the argument to keep HCMV among potential 
co-factors contributing to chronic inflammation that leads to oral tumorigenesis.
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 
(HHV-8), is a herpesvirus that has become a well-known oncovirus in immunocompromised 
individuals infected with HIV [134]. This virus is consistently associated with Kaposi’s 
sarcoma, a cancer developed from cells that line the lymph or blood vessels and usually 
appears as a tumor on the skin or mucosal [135]. Latent transcripts in KSHV include genes 
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and miRNAs that favor viral persistence and replication while promoting host-cell 
proliferation and survival. Furthermore, lytic cycle genes favor viral replication by affecting 
the DNA damage response, reprogramming metabolism, promoting survival, and mediating 
immune evasion, all of which have a role in promoting cancer development [6]. In 2007, 
Morris et al. explored the effects of supernatants from cultures of different bacteria on 
KSHV infected BCLBL-1 cells [136]. They found that metabolic end products from 
pathogens (gram-negative anaerobic periodontopathogens F. nucleatum and P. gingivalis) 
induced lytic replication of KSHV through the activation of a stress-activated MAPK 
pathway in host cells. More specifically, butyric acid from bacteria supernatants were found 
to inhibit cellular HDACs and activate the p38 kinases pathway, resulting in 
hyperacetylation of histones on immediate early viral promoters (Fig. 4C). The targeting of 
HDACs by P. gingivalis is also seen in the reactivation of HIV as we discussed previously.
Epstein–Barr virus (EBV) was the first virus shown to cause cancer in humans and is 
associated with a wide range of human cancers originating from epithelial cells, 
lymphocytes and mesenchymal cells [137]. Infection is transmitted from host to host via 
salivary contact, and the virus passes through the oropharyngeal epithelium to B 
lymphocytes, where it establishes a lifelong latent infection. EBV has three main latency 
patterns, each of which have a role in avoiding host response while promoting B-cell 
survival/proliferation [6]. Although not deeply studied, there is increasing evidence that 
EBV early lytic genes, particularly those encoding homologues of Bcl-2 (BALF1), IL-10 
(BCRF1) and c-fms receptor (BARF1), may be involved in oncogenesis as well as in 
promoting viral infection. Reactivation of the virus and production of progeny contributes to 
several human diseases including nasopharyngeal carcinomas and lymphomas [138]. Similar 
to KSHV and HIV, the latent virus was found to be reactivated upon stimulation with 
supernatant from P. gingivalis (containing high concentrations of butyric acid) through the 
inhibition of HDACs [138]. This inhibition resulted in increased acetylation of adjacent 
histone and transcriptional activation of the BZLF1 promoter, whose gene product ZEBRA 
is known to be the master regulator in EBV transition from latency to lytic state [138] (Fig. 
4D). Taken together with the case of KSHV, there is compelling evidence for the ability of 
butyric acid producing bacteria such as P. gingivalis (main player in periodontitis) to 
reactivate latent herpesvirus infection and contribute to the development of cancer in the oral 
cavity.
As described above, butyric-acid producing bacteria (especially the periodontopathogens P. 
gingivalis) can regulate the viral life cycle in host cells. Periodontopathogens can induce a 
reactivation of HIV which in turn may lead to the opportunistic infection of herpesviruses 
due to immunodeficiency. Latent infection of EBV and KSHV can be reactivated by the 
same bacteria leading to the induction of oncogenes and transformation to malignancy. 
Independent of bacteria, a model of KSHV and EBV co-infection in vitro has shown 
complementing lytic activation [139], suggesting a more complex model of reactivation in 
which periodontopathogens may act in tandem with direct inter-viral interaction to regulate 
infection and the development of cancers. Although HCMV has not been studied extensively 
in the same context, its association with P. gingivalis and periodontal disease offers hints of 
viral-bacterial interaction potentially involving mechanisms used by other herpesviruses.
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6. Human endogenous retroviruses
Endogenous retroviruses (ERVs) are endogenous viral elements located in the genome of 
jawed vertebrates, including humans, and are thought to be relics of ancestral infectious 
retroviruses [140]. Human endogenous retroviruses (HERVs) compose about 4–8% of 
human genome [141]. While there is not enough evidence to solidify the role of HERVs in 
causing human cancers, the connection between the two is constantly been researched [140]. 
Reactivation of HERV expression in cancers [140,142] can contribute to genome instability 
and is suspected to be a prominent player in disease development. Furthermore, resurrection 
of murine leukemia virus (MLV) in immunocompromised mice was found to be dependent 
on intestinal microbiota [143]. In humans, environmental and intestinal microbes were able 
to modulate the transcriptional activity of endogenous retroviruses [144]. It is not clear 
whether this process contributes to cancer development. Nonetheless, multiple studies show 
that upregulated HERV expression in cancerous cells can drive inflammatory responses by 
upregulating type I interferon pathways [145–147] and eliciting T-cell specific antitumor 
immunity [148]. These findings may indicate the role of the immune system in recognizing 
the reactivation of “sleeping” HERVs as a sign of cell transformation and clearing the 
potential threat before it develops into malignancies.
7. Risk factors of virus-associated cancers and microbiome
Risk factors for cancer, such as age, lifestyle, diet and genetics, have been identified but the 
mechanisms underlying their contribution to disease are not always well understood 
[149,150]. The discovery of the role of commensal microbiota and pathobionts in cancer 
development and progression suggests that at least some risk factors may be linked to the 
disease through microbiota. For example, while smoking is a risk factor for nasopharyngeal 
carcinoma [151], it is also associated with dysbiosis in oral microbiota [152], which in its 
turn can contribute to periodontal disease leading to cancer development [153]. In cervical 
cancer, a high number of sexual partners is a well-known risk factor. This association has 
been commonly attributed to increased chances to be exposed to high risk HPV [154]. 
However, women with multiple sexual partners also present disruption of vaginal microbiota 
(bacterial vaginosis) [155,156] that may facilitate chronic HPV infection and cervical cancer 
as discussed earlier (Section 4.1). Another example is liver cancer, for which diabetes and 
obesity have been identified as risk factors [149,157]. Interestingly, in obese people among 
many changes in the gut microbiome, a decrease in Bifidobacterium was reported [158]. 
Because this bacterium has been shown to play a positive role in elimination of HBV (as 
described in Section 3.1), this may partially explain the association between diet-induced 
obesity and liver cancer. Although environmental and hereditary factors make virus-bacteria-
host interactions even more complex to investigate, it is crucial to remember that 
understanding the role of these external factors may become a powerful tool for cancer 
prevention and treatment.
8. Summary
It has recently become evident that progress in the field of virus-associated cancers can be 
enhanced by elucidation of how bacterial microbiota contributes to virus-host interaction. 
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Although the dissection of these transkingdom interactions is evolving [159], we are still in 
the early stages of this journey. Indeed, epidemiological and even some mechanistic studies 
are accumulating. However, the scientific community has not yet reached a unanimous 
agreement on whether any specific cancer requires bacteria-virus interaction for 
carcinogenesis.
Herein, we have described a model of bacteria-virus interactions in the development of 
cancer. We identify two main mechanisms; the first is accomplished by the interaction 
between bacteria and virus resulting in changes in the course of viral infection. The most 
notable example of such mechanism is the inactivation of HIV via bacteria-derived lactic 
acid [97]. The second mechanism is an effect of the bacteria on the host resulting in 
alterations of host susceptibility to viral infection. This can happen in several ways: a) 
bacteria inducing pro-tumor chronic inflammation (e.g. activation of NF-kB pathway 
[6,41,69,92,109,111]), b) commensal bacteria promoting antiviral and antitumor immunity 
(e.g. Bifidobacterium in HBV [53,160]), and c) bacterial metabolite reactivating oncoviruses 
(butyric acid inhibition of host HDAC pathways reactivating HIV [105,106], EBV [138], 
KSHV [136]) (Table 1).
In addition to proposing the model, we identified key questions that have to be answered in 
order to move the field forward (Box 1) and major technological/logistical solutions that are 
required to answer these questions (Box 2).
Finally, treatment of cancer with chemicals and radiation are currently the most popular and 
efficient strategies [161,162]. More recently, our armamentarium was advanced with 
vaccines against oncoviruses [163] and immunotherapy [164], both using the immune 
system to prevent or kill cancer. Unfortunately, neither of these strategies allowed us to 
eliminate completely any oncovirus, nor to cure some cancers.
Therefore, novel approaches are required to significantly change the status quo of this field. 
We believe that this change should come with methods promoting a healthy microbiome, 
development of next generation antibiotics targeting individual bacteria, new probiotics, and 
companion diagnostics that will define a course of personalized/precision medicine for each 
individual patient based on their respective transcriptome and microbiome.
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Box 1
Current trending questions
- Which shifts in microbial communities (presence/absence of particular bacterial 
species or alterations in microbial community structures) can enhance oncogenic 
virus infection progression or, on the contrary, help to eliminate it?
- Which host molecular pathways involved in viral infections and tumorigenesis 
are altered by microbiota?
- Can host genetics shape microbiota toward being anti- or pro-tumorigenic?
- How do microbiota affect the success of anticancer therapies?
- How do antitumor treatments affect microbiota? Are these effects relevant for 
efficient treatments and treatment-related co-morbidities?
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Box 2
Emerging technologies and other solutions
- Experimental approaches for the generation of different types of omics data that 
would allow simultaneous assessment of functional states of each of viruses, host 
and bacteria (e.g. new and improved single cell technologies for both eukaryotic 
and prokaryotic cells).
- Computational tools for the analysis of multi-omics datasets that would provide 
robust predictions of regulatory relationships between all three kingdoms (e.g. 
transkingdom networks [165,166], LEfSe [167]).
- Generation of new experimental models: a) humanized animal models (e.g. 
gnotobiotic animal models for cancer caused by oncogenic viruses harboring 
human microbiota and immune system); b) cell lines and tissues with virus and 
bacteria present (e.g. differentiated 3D cell aggregates colonized with specific 
bacteria [168–173]); c) next generation in vitro models such as organ-on-chip and 
human-on-chip microfluidic devices that allow application of robotic systems.
- Creation of multidisciplinary teams (involving oncologists with expertise in basic 
and clinical science, systems biologist, virologist, microbiologists, and engineers) 
through special funding mechanisms or even the creation of new institutions.
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Fig. 1. 
Model of bacteria-virus interactions in cancer development and progression: A) direct 
interaction between bacteria or bacterial by-products and virus resulting in inhibition or 
promotion of viral infection into host cell; B) indirect interaction between bacteria and virus 
mediated by host response to bacterial stimuli through activation of various pattern 
recognition receptors.
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Fig. 2. 
The interplay between gut microbiome, host and human hepatitis viruses (HCV and HBV): 
A) healthy gut microbiota stimulates host immune system resulting in HBV infection 
clearance; B) Helicobacter pylori invades liver and contributes to chronic inflammation 
induced by HCV; C, D) Helicobacter hepaticus upregulates NF-κB dependent pathways in 
mouse gut (C) and liver (D), synergizing with HCV-related inflammation in the development 
of hepatocellular carcinoma.
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Fig. 3. 
Cervicovaginal microbiota and pathogens can influence the progression of viral infection 
associated with cancer development: A) Lactobacillus spp., predominant bacteria in the 
vaginal microbiome, secretes lactic acid capable of inactivating HIV; B) butyric acid 
secreted by vaginal microbiota induces HIV replication in Human CD4+ T lymphocyte and 
macrophage/monocyte cell lines harboring latent HIV; C) Neisseria gonorrhoeae induces 
IL-6, IL-8 and TNFα production in genital epithelial cells and upregulates HIV gene 
expression in T-cells via heptose-monophosphate induced NF-kB and AP-1 pathways; D) 
domination of vaginal microbiota by Lactobacillus gasseri is associated with faster HPV 
clearance; E) Lactobacillus spp. is able to inhibit the viability of Gardnerella vaginalis and 
Prevotella bivia; F) Prevotella spp. produces ammonia and different amino acids that benefit 
G. vaginalis and Peptostreptococcus anaerobius, contributing to bacterial vaginosis; G) 
Chlamydia trichomatis may influence cervical cancer development, either through synergy 
with HPV or by contributing to local chronic inflammation.
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Fig. 4. 
The role of periodontal disease in head and neck cancers can be mediated by the effects of 
HIV and herpesviruses (EBV and KSHV): A) butyric acid produced by periodontal 
pathogens such as Fusobacterium nucleatum and Porphyromonas gingivalis competitively 
inhibit Histone Deacetylases (HDACs), resulting in the reduced deacetylation of histone 
proteins and sustaining viral gene expression B) activation of HIV proviral gene expression 
through HDAC inhibition increases viral progeny production; HIV infection suppresses 
systemic immune responses and aides in the acquisition of other viral infections; C) 
inhibition of HDAC causes transcriptional activation of the BZLF1 promoter in EBV 
infected cells and results in production of ZEBRA, known switch for lytic cycle activation; 
D) inhibition of HDACs in KSHV-associated cells result in the induction of MAPK and 
expression of lytic genes. Both EBV (C) and KSHV (D) mechanisms promote the spread of 
viral infection and contributes to tumor development.
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